Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Hemosol (HML.TO)

Hemosol (HML.TO)

0.00
-0.00 (0.00%)
0 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Hemosol(HML.TO)

Aug 09, 2005
This could be a time when money moves back into the health care. Usually the small cap biotech stocks, such as Biovale (BVF-T), Patheon (PTI-T), MDS (MDS-T), etc. move together. Don't just buy one, buy 3 or 4 of them. This one is a pretty thin trader, so would stay away from it.
Photo of Bill CarriganBill CarriganUnlock Rating
$1.50

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Jun 13, 2005
Consolidated stock at 4 to 1 to meet Nasdaq requirements. Markets hate reverse consolidations. Typically it's not a good sign as it means you've got too many shares outstanding. Not a great company, so wouldn't expect a whole lot from this company in the future.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$1.75

Stock price when the opinion was issued

biotechnologypharmaceutical
TRADE

Hemosol(HML.TO)

Feb 09, 2004
Speculative future.
Photo of Michael SprungMichael SprungUnlock Rating
$1.58

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Hemosol(HML.TO)

Jan 28, 2004
It will expire again, company has run out of money many times. Take money out, while money is on the table.
Photo of Andrew McCreathAndrew McCreathUnlock Rating
$1.62

Stock price when the opinion was issued

biotechnologypharmaceutical
SELL

Hemosol(HML.TO)

Jan 26, 2004
Basically, you are paying for an option. The company has run out of money many times and they continue to have regulatory problems with their product.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$1.56

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Dec 15, 2003
Built a nice plant in Mississauga, but found they had trouble with their blood substitute. Now a speculative stock.
Photo of Gavin GrahamGavin Graham
No
Unlock Rating
$1.58

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Dec 08, 2003
Have made arrangements with another biotech company by contracting for part of their facility. Should be getting some revenues. Not a fan.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$1.70

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Dec 08, 2003
A speculative play. Hemalink stalled in face two clinical trials. Build a plant. Limited visibility going forward.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$1.70

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Sep 05, 2003
Ran into trouble with their lead product. Down to about $900,000 in cash. The company is on life support.
Photo of Lou SchizasLou SchizasUnlock Rating
$0.87

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Mar 31, 2003
Very speculative. FDA trials didn't go well.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$0.72

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Mar 17, 2003
A lot of problems. May not survive.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$0.62

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Jan 14, 2003
A long way from being a mature company with mature products. Speculative.
Photo of David BaskinDavid BaskinUnlock Rating
$2.89

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Jan 14, 2003
Never seems to get it together.
Photo of Michael SmedleyMichael SmedleyUnlock Rating
$2.89

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Hemosol(HML.TO)

Dec 05, 2002
Worst is behind them. Would prefer owning through MDS.
Photo of John ZechnerJohn ZechnerUnlock Rating
$2.50

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Hemosol(HML.TO)

Nov 07, 2002
OK for a long term hold. Buy on weakness.
Photo of Bruce Campbell (1)Bruce Campbell (1)Unlock Rating
$1.90

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 1 to 15 of 78 entries

Hemosol (HML.TO) Frequently Asked Questions

What is Hemosol stock symbol?

Hemosol is a OTC stock, trading under the symbol HML.TO (previously HML-T on Stockchase) on the undefined (undefined). It is usually referred to as or HML.TO

Is Hemosol a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on HML.TO (previously HML-T on Stockchase) on Stockchase. Read the latest expert commentary for Hemosol.

Is Hemosol a good investment or a top pick?

Hemosol was recommended as a Top Pick by Bruce Campbell (1) on 2002-11-07. Read the latest stock experts ratings for Hemosol.

Why is Hemosol stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Hemosol.

Is Hemosol worth watching?

Hemosol is covered by Stockchase experts and is worth watching.

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video